Skip to content

Cognitive

PE-22-28

InjectableEvidence CEvery day
Half-life
1hours
Typical vial
5 / 10mg
Research amounts
100–300mcg

per administration

Common schedule
Every day
Animal or lab only

Only animal or lab studies exist — no human study has set an amount.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded6units dialled
Concentration
1.67mg/mL
Volume per draw
0.06mL
Units to dial
6
Doses per cartridge
50

Vial label

Copy this into your label printer.

Published research contexts for PE-22-28 describe 100300 mcg per administration. Descriptive only, not a recommendation.

Spadin itself clears within minutes; the PE 22-28 analog was engineered for greater stability, but human pharmacokinetics are unpublished, so this is a rough placeholder.

Evidence is preclinical: a shortened, stabilised analog of spadin that blocks the TREK-1 potassium channel, studied in rodent mood and neurogenesis models. No human dose-ranging data fixes an amount or schedule and the figures are community-derived, so no schedule table is shown.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.00× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
5hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • PE 22-28 / spadin TREK-1 literature (Mazella/Borsotto)A spadin-derived TREK-1 blocker reported to raise neurogenesis and antidepressant-like activity in mice; no human dosing literature.

Next steps